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ABSTRACT
CONTEXT AND OBJECTIVE: The only effective treatment for patients who have severe reactions after Hymenoptera stings is venom immunotherapy. 
The aim of this study was to review the literature to assess the effects of venom immunotherapy among patients presenting severe reactions after 
Hymenoptera stings. 
DESIGN AND SETTING: Randomized controlled trials in the worldwide literature were reviewed. The manuscript was produced in the Discipline of Allergy 
and Clinical Immunology, Universidade de São Paulo (USP).
METHODS: Randomized controlled trials involving venom immunotherapy versus placebo or only patient follow-up were evaluated. The risk of systemic 
reactions after specific immunotherapy was evaluated by calculating odds ratios (OR) and their 95% confidence intervals.
RESULTS: 2,273 abstracts were identified by the keywords search. Only four studies were included in this review. The chi-square test for heterogeneity 
showed that two studies were homogeneous and could be included in a meta-analysis. By combining the two studies, the odds ratio became significant: 
0.29 (0.10-0.87). However, analysis on the severity of the reactions after immunotherapy showed that the benefits may not be so significant because the 
reactions were mostly similar to or milder than the original reaction. 
CONCLUSIONS: Specific immunotherapy should be recommended for adults and children with moderate to severe reactions, but there is no need to 
prescribe it for children with skin reactions alone, especially if the exposure is very sporadic. On the other hand, the risk-benefit relation should always 
be assessed in each case. 
ReSumo
CONTEXTO E OBJETIVO: O único tratamento eficaz para pacientes que têm reações graves após ferroada de Hymenoptera é a imunoterapia com veneno. 
O objetivo deste estudo foi rever a literatura para avaliar os efeitos da imunoterapia com veneno em pacientes com reações graves após ferroada de 
Hymenoptera.
TIPO DE ESTUDO E LOCAL: Foram revisados na literatura mundial ensaios clínicos controlados e aleatórios. O manuscrito foi realizado na Disciplina de 
Alergia e Imunologia Clínica, Universidade de São Paulo (USP).
Métodos: Ensaios clínicos controlados e aleatórios envolvendo imunoterapia com veneno de Hymenoptera versus placebo ou apenas acompanhamento 
dos pacientes foram avaliados. Realizada imunoterapia específica, o risco de reações sistêmicas foi avaliado através de cálculo do “odds ratio” e intervalo 
de confiança de 95%. 
RESULTADOS: 2.273 resumos foram identificados na busca pelas palavras chave. Apenas quatro estudos foram incluídos nesta revisão. O teste qui-
quadrado de heterogeneidade mostrou que dois estudos foram homogêneos e puderam ser incluídos na metanálise. Ao combinar os dois estudos, o 
“odds ratio” passou a ser significativo: 0.29 (0.10-0.87). Entretanto, ao analisar a gravidade das reações ocorridas após a imunoterapia, observou-se 
que os benefícios podem não ser tão relevantes, pois as reações foram, na grande maioria, ou mais leves ou semelhantes à reação original. 
CONCLUSÕES: A imunoterapia específica deve ser recomendada para adultos e crianças com reações moderadas a graves, porém não há necessidade 
de prescrevê-la para as crianças apenas com reações cutâneas, especialmente se a exposição é muito esporádica. No outro lado, a relação risco-
benefício deve ser sempre avaliada em cada caso.
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INTRoDuCTIoN
Insects of the order Hymenoptera (bees, wasps and ants) have been 
exhaustively studied in medicine, not only because of the therapeutic 
possibilities of venom components, but also because of the intensity and 
severity of the allergic reactions that their venom causes. Drugs, foods, 
latex and Hymenoptera venom are the most commonly reported culprits 
for anaphylaxis.1 Recent studies have suggested that the prevalence of 
Hymenoptera sting allergy is about 0.4% to 3.3%.2 
The clinical manifestations produced by Hymenoptera venom can 
be didactically classified into allergic reactions (extensive local reaction, 
anaphylactic systemic reaction and late systemic reaction) and non-al-
lergic reactions (local reaction and toxic systemic reaction).3,4
The treatment for systemic allergic reactions to Hymenoptera venom 
consists of emergency treatment and specific allergen immunotherapy, 
which is considered to be a safe and effective treatment.5 However, its 
real success rate seems to vary between different centers, because the re-
sults are based on non-controlled studies and are normally limited by 
the sample size and the low statistical power.
Therefore, a systematic review of the worldwide literature is very im-
portant from the scientific point of view, in order to critically assess all 
the studies already produced, and to organize and compare data using 
systematic methods.
oBJeCTIVeS
The objectives of the present study were:
To perform a systematic review of published and non-published 
studies in the worldwide literature on Hymenoptera venom immuno-
therapy among patients who presented systemic allergic reactions after 
insect stings. Therefore, all randomized trials comparing Hymenoptera 
venom immunotherapy with placebo or emergency treatment (for ex-
ample, epinephrine autoinjection ) would be identified;
To assess the methodological quality of these randomized con-
trolled trials; 
To determine the heterogeneity of the studies, and analyze possible 
differences among the several types of treatment. 
meTHoDS
Types of studies
Any randomized controlled trials examining treatment given to pa-
tients who presented systemic allergic reactions to Hymenoptera stings, 
in which immunotherapy was administered by injection, were eligi-
ble for inclusion in this review. Other administration routes, such as 
sublingual or oral, were excluded. Only randomized controlled trials 
were included, in order to reduce the bias that is associated with oth-
er types of studies. The allergen extracts administered were: honeybee, 
wasp (yellow jacket, white hornet, yellow hornet and Polistes sp.) and 
ant (Solenopsis invicta and Myrmecia pilosula). The co-interventions in-
cluded placebo or emergency treatment (follow-up alone for patients 
who were given guidance for adrenaline self-administration, using an 
epinephrine autoinjector). The trials were included even if they were 
single-blind.
Types of participants enrolled in the studies
The participants were children and adults of both sexes with Hy-
menoptera venom hypersensitivity, as defined by a history of systemic 
anaphylactic reaction after insect stings and the presence of a positive 
skin test (prick or intradermal test).
Types of intervention
Hymenoptera venom immunotherapy was compared with placebo 
and with no treatment (follow-up or use of an epinephrine self-admin-
istration device. i.e. an epinephrine autoinjector).
The following items were accepted as exclusion criteria: history 
of systemic hypertension, heart disease or poorly controlled lung dis-
ease; and use of angiotensin-converting enzyme (ACE) inhibitors, beta-
blocker therapy or a negative skin test.
Types of outcome measurements
- Change in clinical manifestation after sting challenge or accidental 
stings.
- Indication for venom immunotherapy. 
- Change in levels of venom-specific immunoglobulin E (IgE) or im-
munoglobulin G (IgG) antibodies.
Search strategy to identify studies
(i) Strategy to locate randomized controlled trials
(ii) Strategy to locate the insect terms
bees.mp. or exp BEES/
bee venom.mp. or exp Bee Venoms/
honeybee.mp.
hymenoptera.mp. or exp HYMENOPTERA/
wasps.mp. or exp WASPS/
wasp venom.mp. or exp Wasp Venoms/
white hornet.mp.
yellow jacket.mp.
yellow hornet.mp.
polistes.mp.
ants.mp. or exp ANTS/
ant venom.mp. or exp Ant Venoms/
solenopsis invicta.mp.
myrmecia pilosula.mp.
(iii) Strategy to locate types of reactions
exp “Insect Bites and Stings”/
exp HYPERSENSITIVITY, DELAYED/ or exp HYPERSENSI-
TIVITY/ or hypersensitivity.mp. or exp HYPERSENSITIVITY, IM-
MEDIATE/
exp Anaphylaxis/ or anaphylactic.mp.
(allergic or allergy).mp.
swelling.mp.
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exp EDEMA/ or edema.mp.
systemic reaction.mp.
shock.mp. or exp SHOCK, TRAUMATIC/ or exp SHOCK/
exp INFLAMMATION MEDIATORS/ or inflammation.mp. or 
exp INFLAMMATION/
hives.mp. or exp Urticaria/
exp Airway Obstruction/ or angiodema.mp.
laryngeal obstruction.mp.
bronchospasms.mp. or exp Bronchial Spasm/
gastro-intestinal symptoms.mp.
vasculitis.mp. or exp VASCULITIS, ALLERGIC CUTANEOUS/ 
or exp VASCULITIS/ or exp VASCULITIS, HYPERSENSITIVITY/
glomerulonephritis.mp. or exp GLOMERULONEPHRITIS/
polyradiculitis.mp. or exp Polyradiculopathy/
exp DEATH, SUDDEN/ or exp DEATH/ or death.mp.
(iv) Strategy to locate types of reactions
exp IMMUNOTHERAPY, ACTIVE/ or immunotherapy.mp. or 
exp IMMUNOTHERAPY/
adrenaline.mp. or exp Epinephrine/
exp Injections/ or epipen.mp.
Searches were conducted to identify randomized controlled trials, 
in any language, going from the dates when the following databases be-
gan: Medline (Medical Literature Analysis and Retrieval System On-
line), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da 
Saúde), Embase (Excerpta Médica Database), SciSearch (Science Cita-
tion Index Expanded), SciELO (Scientific Electronic Library Online) 
databases and the Cochrane Database of Systemic Reviews. Reference 
lists of recent reviews and published trials were also searched.
The decisions on whether to include studies in the review were 
made through discussion between two of the review authors (ASW and 
LAMF), after all of the studies had been read by ASW. For trials that 
seemed to meet the inclusion criteria or for which there was insufficient 
information in the title and abstract to make a clear decision, the full 
reports were obtained.
Each of the suitable reports was read in detail by ASW, and relevant 
information was abstracted onto a standard extraction sheet (covering 
study type and methodology, number and description of subjects, de-
tails of type, dosage and time schedule/duration of intervention, type, 
timing and measurement method for outcomes). All data were extract-
ed and ASW and LAMF independently assessed the methodological 
quality of the studies included, using a validated quality checklist.6 This 
instrument could only assess some items and its use to include or ex-
clude systematic review studies is not recommended. Nonetheless, it 
was able to join homogeneous studies together for sensitivity analysis, 
with a view to meta-analysis. 
Data collection
The following inclusion criteria were assessed: how the randomiza-
tion was carried out, blinding, whether the intervention was defined 
and what descriptions were provided for the experimental group and 
control group.
The information gathered on the included studies consisted of de-
tailed descriptions of the methods, participants, interventions, out-
comes, numbers and reasons for withdrawals.
The methodological quality was assessed in order to identify poten-
tial sources of bias.
Statistical analysis
The outcome data were extracted and the odds ratio (OR) and 95% 
confidence intervals (CI) were analyzed for individual studies, consider-
ing only the patients who had had systemic allergic reactions to insect 
stings or challenge. 
To assess the heterogeneity between studies, chi-square tests were 
performed. In these, a P value < 0.05 indicated significant differenc-
es between studies and raised questions regarding whether the results 
could be meaningfully combined.
Description of studies
The search for articles in the different databases, using the pre-
determined key words, resulted in 2,265 articles. The search through 
bibliographic references added another eight articles. After the first 
selection, 178 studies remained. Through the second and more rig-
orous filter, only four controlled studies that were published between 
1996 and 2008 were found to satisfy all the inclusion criteria. The 
methodologies, participants, interventions and results of the studies 
included are listed in Table 1.7-10 Overall, 306 participants were in-
volved in the four selected studies. The participants’ ages ranged from 
two to 65 years. Only one study compared ant venom immunother-
apy with placebo, while three studies compared bee and wasp im-
munotherapy with placebo or patient follow-up. The main reasons 
for excluding 174 studies were non-randomization and the lack of 
proper controls.
methodological quality
In accordance with the Jadad scale, the methodological quality of 
the trials included was as follows: one study received the maximum 
grade of five, according to the quality scores, and three studies received 
grade three. The articles excluded could not be classified because the 
published data did not include any detailed assessments. With regard to 
blinding of the participants, which is an important factor for reducing 
bias in controlled and randomized trials, only one study was double-
blind and three were single-blind (Table 2).7-10
ReSuLTS
The article search in the databases, using the predetermined key 
words, resulted in 2,273 articles. The search through the bibliographic 
references contributed another eight articles. After an initial analysis of 
titles, abstracts and complete texts, only 178 articles remained. Among 
these, after a second, more rigorous selection, only four studies matched 
all the inclusion criteria for a meta-analysis.
The study by Hunt et al.7 was the first trial on immunotherapy us-
ing insect venom, and it compared bee venom use with placebo and 
with whole-body extract in a single-blind manner. At the end of the 
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treatment, the venom reactions were tested by insect challenge and the 
authors found the following systemic reactions: 
- Group I (venom): One patient was unable to achieve tolerance of an 
adequate venom dose before the study ended and only one patient 
exhibited urticaria after sting challenge.
- Group II (whole body) and Group III (placebo): There were no ad-
verse reactions to immunotherapy. Ten patients presented systemic 
reactions of urticaria type, two patients presented generalized itch-
ing and skin rash and three patients experienced hypotension after 
sting challenge.
The odds ratios of each group for systemic reactions after sting chal-
lenge were:
- Group I versus Group III: OR = 0.10 (0.01 < OR < 0.68)
- Group I versus Group II: OR = 0.09 (0.01 < OR < 0.62)
- Group II versus Group III: OR = 1.09 (0.57 to 2.10)
These data indicate that, concerning the reaction risk, the patients 
who were treated with the whole-body extract did not differ from those 
treated with placebo. However, the results presented by specific immu-
notherapy with Hymenoptera venom, in relation to placebo and whole-
body extract, proved that this was a safe and effective therapeutic meth-
od for patients who presented with severe allergic reactions after insect 
stings. It was not possible to determine the relationship between the 
quantity of IgG antibodies and protection because there was no statisti-
cal difference between the groups.
In the study by Schuberth et al.,8 only children with non-severe sys-
temic reactions were selected to receive insect venom immunotherapy 
(bee or wasp) or no treatment. The treated and untreated groups pre-
sented approximately the same specific IgG levels for venom, and these 
values decreased in the untreated group during the study (7.68 ± 15.9 
to 2.1 ± 4.14 µg/ml).
The authors tried to identify a correlation between predictive fac-
tors such as age, gender, skin test or IgE level with reactions. However, 
no correlation between these parameters was identified. After the end of 
the immunotherapy, the authors chose not to perform sting challenges, 
but to follow up potential accidental stings. The systemic reaction ratios 
per sting and per stung patient were low in both groups, and the differ-
ence was not statistically significant. No reaction more severe than the 
original one occurred in the treated group, and only one of the eight sys-
temic reactions in the untreated group was as severe as the original one. 
In a comparison between the groups, we obtained the odds ratio value 
of 0.35 (0.05 < OR < 2.56), which was non-significant.
In the third selected study, Valentine et al.9 performed a trial similar 
to the previous one, among children who presented reactions restricted 
Table 1. Characteristics of included studies
Hunt et al.7 Schuberth et al.8 Valentine et al.9 Brown et al.10
Participants History of generalized allergic 
reactions after insect stings and 
positive skin test. 
History of generalized allergic 
reactions with cutaneous mani-
festations after insect stings and 
positive skin test. 
One or more systemic insect sting 
reactions confined to the skin and 
positive skin test. 
History of grade II-IV hypersensitiv-
ity to ant and positive skin test. 
Exclusion criteria Ambiguous histories and negative 
skin test.
Children with more serious cardio-
vascular or respiratory symptoms.
Signs or symptoms of more severe 
reaction (hoarseness, dyspnea, 
bronchospasm or cardiovascular 
involvement).
History of hypertension, heart 
disease, poorly controlled lung 
disease, ACE inhibitor or beta-
blocker therapy.
Diagnostic criteria Generalized allergic reactions and 
positive skin test
History of systemic insect sting 
reaction, positive venom skin (hon-
eybee, yellow jacket, yellow hornet, 
Polistes) and IgE antibodies
History of systemic insect sting 
reaction, positive venom skin (hon-
eybee, yellow jacket, yellow hornet, 
white faced hornet and Polistes)
History of systemic insect sting 
reaction (grade II-IV) and a posi-
tive skin test. 
Age All ages 3 to 16 years 2 to 16 years 17 to 65 years
Percent males Groups were matched for age 
and sex
Treatment: 68.7%
No treatment: 71.4%
Treatment: 70%
No treatment: 75%
Treatment: 63%
Placebo: 62%
Interventions Specific venom immunotherapy: 
group I (n = 19)
Whole-body insect extract immu-
notherapy: group II (n = 20)
Placebo (histamine solution): 
group III (n = 20)
Specific venom immunotherapy 
(n = 32)
No treatment (n = 42)
Specific venom immunotherapy 
(n = 45) 
No treatment (n = 61)
Specific ant venom immunothera-
py (n = 35)
Immunotherapy with placebo (n 
= 32)
Outcomes: % systemic reactions 
after sting challenge (systemic 
reactions)
Group I: 5% (1)
Group II: 64% (7)
Group III: 58% (7)
Treatment group: 5.9% (1)
No treatment group: 17% (8)
Treatment group: 4.2% (1)
No treatment group: 25.9% (7)
Treatment group: 3% (1)
Placebo group: 72% (21)
Odds ratio (CI) Group I versus III: 0.04 (0.01 < 
OR < 0.68)
Group I versus II: 0.09 (0.01 < OR 
< 0.62)
Group II versus III: 1.09 (0.57 < 
OR < 2.10)
0.35 
(0.05 < OR < 2.56)
0.16 
(0.02 < OR < 1.21)
0.04 
(0.01 < OR < 0.28)
Notes Drop out: 0 Drop out: 0 Drop out: 0 Drop out: 0 
Allocation concealment B B B A
Table 2. Methodological quality of the included studies according to 
Jadad score
Study Jadad score
Hunt et al.7 3
Schuberth et al.8 3
Valentine et al.9 3
Brown et al.10 5
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to the skin (urticaria and angioedema). The patients were randomized 
to receive immunotherapy with insect venom (bee or wasp) or not. The 
analyses on the characteristics of the two groups did not reveal any dif-
ferences relating to age, gender, IgE or specific IgG levels or even to skin 
test results. With regard to systemic reactions after the sting challenge, 
there was only one case of a systemic reaction in the group treated with 
immunotherapy. In the untreated group, the great majority of the re-
actions were milder than the reactions presented previously, while two 
were of similar severity and none of them were more severe. The odds 
ratio obtained in our analyses was 0.16 (0.02 < OR < 1.21). From this 
information, we believe that immunotherapy for children with reactions 
restricted to the skin is unnecessary.
The only double-blind, placebo-controlled study was performed 
by Brown et al.10 In the study, patients of all ages with severe systemic 
allergic reactions to ants (Myrmecia pilosula) were selected. After one 
week with two successive maintenance doses, insect challenges were per-
formed. The systemic reactions presented in the placebo group were: 
seven patients with grade I, three with grade II, three with grade III and 
eight with grade IV. In the specific immunotherapy group, there was 
just one patient with a grade I systemic reaction. From these results, the 
odds ratio value was 0.04 (0.01 < OR < 0.28), thus proving that the pro-
cedure was an effective treatment.
After performing the chi-square test (chi-square for heterogene-
ity = 0.24; P = 0.623) with the aim of evaluating the heterogeneity of 
the studies, only two studies8,9 were found to be homogeneous with 
each other. As mentioned earlier, the study by Schuberth et al.8 (1983) 
showed an OR for systemic reactions after accidental stings of 0.35 
(0.05 < OR < 2.56), while the study by Valentine et al.9 showed a calcu-
lated OR of 0.16 (0.02 < OR < 1.21). After meta-analysis on these two 
studies, the OR became 0.29 (0.10 < OR < 0.87) (Table 3).
DISCuSSIoN
This is the second systematic review performed to assess the level 
of evidence for the use of specific immunotherapy with insect venom 
among patients with systemic allergic reactions. The previous system-
atic review11 evaluated eight articles, but it also included observational 
studies. The authors of the previous review concluded that the findings 
showed that specific immunotherapy was effective for treating hyper-
sensitivity to Hymenoptera venom.
Our review therefore differed from the previous one by adopting 
methodology for systematic reviews that only considered randomized 
clinical trials to be within the inclusion criteria. Overall, 2,273 articles 
on this subject were found in the worldwide literature, using the prede-
termined key words. From these, 2,269 articles were excluded from this 
review and just four articles matching all the predetermined inclusion 
criteria were selected. All of these four articles were written in English. 
It was found that no randomized controlled trials had been published 
in other languages.
The statistic analysis for heterogeneity, which took into account the 
participants’ characteristics, type of study and outcome, was significant 
for only two studies: Schuberth et al.8 and Valentine et al.9 This resulted 
in an OR of 0.24 and P = 0.623. Consequently, because P was greater 
than 0.05, we could conclude that these two studies were not heteroge-
neous and could be included in the meta-analysis. The two remaining 
articles, as demonstrated in Table 1, differed from these two articles for 
two main reasons: the patients recruited were not children and those pa-
tients presented severe reactions (grade II to IV) that were not restricted 
to the skin.
The reason why there are only a few prospective trials that were 
placebo-controlled and included subjects that presented hypersensitiv-
ity to insect venom probably relates to the severity of the allergic reac-
tions. In many cases, these reactions might be fatal. Specific-venom im-
munotherapy has been considered by most authors to be highly effec-
tive, therefore precluding the use of placebo. This is very evident in the 
study by Hunt et al.,7 which demonstrated clearly that immunotherapy 
with insect venom was safe and an effective therapeutic method among 
high-risk patients.
Strength of evidence
The effectiveness of immunotherapy was evaluated by re-exposure 
to the cited allergen, through an accidental sting or a sting challenge.
The analysis presented as Figure 1 shows that after performing the 
meta-analysis on the two studies, the combined odds ratio calculated us-
ing Peto’s random method for systemic reactions after immunotherapy8,9 
Ratio of treatment to control systemic reaction
Schubert et al.8
Valentine et al.9
0.05
0.16
0.02
0.10
0.29 0.87
1.21
(1.0) (0.5) 0.0
2.56
0.5 1.0 1.5 2.0 2.5 3.0
Better Worse
Figure 1. Meta-analysis on two studies8,9 comparing Hymenoptera 
venom immunotherapy versus follow-up alone (no treatment), among 
patients (children) who had only presented skin reactions to the first sting. 
Presentation of the results from systemic reactions after ending the treatment, 
according to odds ratio and 95% confidence intervals (Peto’s method).
Table 3. Meta-analysis on two studies8,9 comparing Hymenoptera venom 
immunotherapy (experimental group) versus control group. Presentation 
of the results from the systemic reactions caused by the provocation test 
or an accidental sting after ending the immunotherapy, according to odds 
ratios and 95% confidence intervals
Meta Online
Groups
Studies Experimental Control Peto OR
n n n n (95% CI; random model)
Schuberth et al.8 1 17 8 47 0.35 (0.05 to 2.56)
Valentine et al.9 1 24 7 27 0.16 (0.02 to 1.21)
Total 2 41 15 74 0.29 (0.10 to 0.87)
5% 20%
OR = odds ratio; CI = confidence interval.
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became 0.29 (CI: 0.10 to 0.87). Taken individually, the odds ratio in 
the study by Schuberth et al.8 was 0.35 (CI: 0.05 to 2.56) and in Val-
entine et al.,9 it was 0.16 (CI: 0.02 to 1.21). Consequently, by perform-
ing the meta-analysis on the two studies conjointly, we were able to “in-
crease” the sample size. Thus, the non-significant odds ratios and the re-
spective confidence intervals that included the unit in the separate stud-
ies became significant values in combination.
Another possible method for interpreting the data would be to ana-
lyze the percentage of systemic reactions (Table 3). After the meta-anal-
ysis, we found that in the experimental group (treated), the incidence of 
systemic reactions was 5%, while in the control group (untreated), the 
incidence was 20%.
The lack of allocation concealment and the fact that the studies were 
not double-blind may possibly have resulted in overestimation of the 
effects of treatment. These aspects of the study design were poorly de-
scribed. Publication bias is also possible, but few studies were available 
for determining such occurrences.
Applicability
The above data indicate that specific immunotherapy is effective 
among children with systemic reactions restricted to the skin. Never-
theless, when the severity of the reaction that occurred after the sting 
challenge or accidental sting is taken into account, it is observed that 
the benefits are non-significant. In the study by Schuberth et al.,8 
the reactions that occurred after reexposure to stings, not only in the 
group that received specific immunotherapy but also in the group that 
did not, were milder than the original ones. These characteristics were 
also observed in the study by Valentine et al.9: 84 stings among the 
children who received the immunotherapy resulted in only one sys-
temic reaction; while in the group that was not treated, 196 stings re-
sulted in 18 systemic reactions. Even though the number of reactions 
was significantly higher in the untreated group, 16 of the 18 reactions 
were milder than the original one and two were similar in severity to 
the original reaction.
Consequently, since there are no data showing severe systemic reac-
tions involving the respiratory and/or cardiovascular system, there is no 
need for immunotherapy among children who present only a skin reac-
tion. This was also found in an important study by Golden et al.12 that 
assessed the evolution of hypersensitivity to Hymenoptera venom after a 
time period that ranged from six to 32 years by comparing a group of 
children that received immunotherapy and another group that did not 
receive specific immunotherapy. Among the patients who did not re-
ceive treatment and who had a history of mild systemic reactions, 87% 
did not present a systemic reaction after reexposure to the sting. Six pa-
tients presented skin reactions, six presented moderate reactions and 
in no case was the reaction more severe. The authors recommended, 
backed by their results, that specific immunotherapy should be imple-
mented for children with moderate to severe reactions, but did not indi-
cate such therapy for patients with mild reactions, because the observed 
risk of severe reactions was lower than 5%.
The other two studies7,10 were considered to be trials of good meth-
odological quality, but could not be included in the meta-analysis due 
to the heterogeneity between them.
The study by Hunt et al. was the first controlled trial in the world-
wide literature, and it recommended the use of immunotherapy with 
purified venom.7 The therapy used until that study had been prepared 
using whole-body extracts from bees and wasps. These authors assessed 
the allergenic potential of these extracts in laboratories and observed, 
through histamine release by basophils, that the allergens to which the 
patients were sting-insect sensitive were not present in the whole-body 
extract but in the purified venom. The study by Hunt et al.7 was un-
doubtedly a very important milepost within this field, because it com-
pares the use of placebo, whole-body extract and venom for insect ven-
om allergy diagnosis and therapy. The results obtained by these authors 
demonstrated that treatment with whole-body extract and placebo did 
not differ between each other, while specific-venom immunotherapy 
showed effectiveness of 98%.
In the study by Brown et al.,10 which was considered to be of high 
methodological quality because it was double-blind and placebo-con-
trolled, the selected patients presented severe systemic reactions to the 
venom of the jack jumper ant (Myrmecia pilosula), which accounts for 
approximately 90% of anaphylaxis to insect venom in southeastern Aus-
tralia. The odds ratio for systemic reactions after sting challenge was cal-
culated to be 0.04 (CI: 0.01 to 0.28), thus demonstrating that specific 
immunotherapy had a protective effect. Seventy-two percent of the sys-
temic reactions occurred after performing a sting challenge in the pla-
cebo group (seven grade I reactions, three grade II, three grade III and 
eight grade IV), while 3% of the reactions in the immunotherapy group 
(only one grade I reaction) were systemic. Among the adverse reactions 
to immunotherapy, 22 of the 64 cases reported by patients were con-
sidered to be objective reactions (34%) and, in two cases, there was a 
decrease in arterial pressure. The substantial risk of a severe reaction to 
an additional sting among untreated patients was approximately 70% 
(95% CI: 61-78). This rate was much higher than the 27% to 57% re-
ported for bee or wasp allergy.13 One important observation that must 
be made in this regard is that the study by Brown et al. was the only 
controlled trial on ant (Myrmecia pilosula) venom reactions. It needs to 
be born in mind that in Brazil14 and in the United States15, ants are re-
sponsible for a large number of accidents, particularly among children, 
and the most important ant type is Solenopsis sp.14,15
The hypersensitivity that occurs due to fire ant (Solenopsis sp) venom 
is an increasing and important cause of morbidity and mortality in the 
United States. In 1989 alone, 32 deaths resulted from accidents with these 
insects.16 Although whole-body extract is ineffective in relation to the 
venom of bees, wasps and jack jumper ants, this type of extract continues 
to be used for treating allergies relating to Solenopsis sp ant venom,17 with 
a very satisfactory clinical response. This is because considerable quanti-
ties of venom can be found in the whole-body extract (approximately 
20 µg per dose).18 There are no double-blind, placebo-controlled studies 
assessing the effectiveness of these studies. There are only observational 
studies that have validated immunotherapy with whole-body extract to 
treat hypersensitivity to the venom from this type of ant.19-21
other relevant information
Even though the evidence is based only on one trial7 and on ob-
servational studies,11,22-25 the efficacy of specific-venom immunother-
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apy for avoiding anaphylaxis to bee stings or venom is well accepted. 
This recommendation can be found in an important manual26 pub-
lished conjointly by three major allergy and immunology societies: 
the American College and the American Academy of Allergy, Asth-
ma and Immunology (ACAAI and AAAAI); and the Joint Council of 
Allergy, Asthma and Immunology. This publication recommends im-
munotherapy for patients who present a history of systemic allergic 
reaction to Hymenoptera venom, as demonstrated by the presence of 
specific IgE antibodies. For patients who present with an anaphylac-
tic history after an insect sting, especially if there were severe reactions 
such as airway obstruction or hypotension, immunotherapy must be 
considered. For children below 16 years of age who present with skin 
reactions alone, immunotherapy is not normally recommended. For 
adults who only present reactions restricted to the skin, there is some 
controversy regarding the treatment, but immunotherapy is usually 
recommended. The risk of a subsequent systemic reaction decreases 
to less than 5% and, among individuals who still have reactions, these 
are of a milder intensity.27
In cases in which there is doubt, it is important to assess the risk-
benefit relationship of immunotherapy, in an attempt to assess the 
likelihood of a severe reaction from a future exposure. Consequent-
ly, the clinical decision regarding whether to start immunotherapy 
must include an epidemiological assessment on the natural history.27,28 
In the case of insect venom allergy, it is firstly important to determine 
the individual’s risk of presenting another allergic reaction when again 
stung, i.e. the reexposure risk. Secondly, the likelihood of being stung 
again needs to be assessed: this depends mainly on lifestyle and expo-
sure to the insect. Thirdly, the correct etiological diagnosis needs to be 
established, with identification of any events that caused sensitization 
to the venom responsible for the reaction.
The prevalence of systemic reactions after insect stings is low, 
but the fear of a more severe reaction or even the idea that death 
might result from the stings may produce a negative effect regarding 
patients’ emotional state and social activities. In a study by Antoni-
celli et al.,29 the mortality rate due to insect venom allergy was low, 
but half of those deaths could have been avoided among patients 
with a history suggestive of allergy, had immunotherapy been per-
formed. Exemplifying this, in an open and controlled study, patients 
were randomized to receive immunotherapy or were advised to use 
adrenaline, if necessary (epinephrine autoinjector). A quality-of-life 
questionnaire was distributed one year before and one year after the 
immunotherapy or the used of the epinephrine autoinjector. Among 
the patients who were allergic to wasp venom, there was a clinically 
significant improvement in those who were treated with immuno-
therapy, compared with patients who were only advised to use adren-
aline if necessary.30
CoNCLuSIoN
Treatment of hypersensitivity to Hymenoptera venom with the use 
of specific-allergen immunotherapy is an important method through 
which allergists can modify the course of the disease and improve pa-
tients’ quality of life, not only from the psychological perspective but 
also from the objective point of view, by reducing the intensity of sys-
temic reactions.
Specific-venom immunotherapy should be recommended for adults 
with systemic reactions and for children with moderate to severe reactions, 
but there is no need to prescribe it for children who only present skin re-
actions after an insect sting, especially if the exposure is very sporadic. Im-
portantly, the risk-benefit relationship should be assessed in each case.
Little is known about the natural history of hypersensitivity to So-
lenopsis sp. and the effectiveness of immunotherapy, unlike the situation 
regarding other insects. Whole-body extract of Solenopsis sp. has been 
shown to contain important venom allergens, and evidence support-
ing the effectiveness of immunotherapy with whole-body extract is con-
tinuing to be accumulated over the course of time, in spite of the lack of 
placebo-controlled trials.
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